Literature DB >> 34846681

French-Canadian families from Saguenay-Lac-Saint-Jean: a new founder population for APECED.

Tania Cruz Marino1, Hélène Villeneuve2, Josianne Leblanc3, Caroline Duranceau2, Philippe Caron2, Charles Morin4, Marcel Milot4, Raphaëlle Chrétien4, Maude-Marie Gagnon5, Jean Mathieu6, Benjamin Ellezam7, Daniela Buhas8.   

Abstract

PURPOSE: Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is more prevalent in some founder populations, but relatively unexplored in Canada. This study aimed at investigating the French-Canadian patients through phenotypic and genotypic characterization.
METHOD: Phenotype and demographic characterization were done for 12 affected individuals belonging to eight unrelated families. Samples from 11 cases were analyzed in a molecular clinical laboratory, and muscle biopsies were reviewed for two individuals with a limb-girdle muscle dystrophy.
RESULTS: The clinical phenotype was similar to that observed in European Caucasian populations but differed in the non-endocrine spectrum from the American-reported series of cases. Two cases exhibited a limb-girdle muscle dystrophy, and we found preliminary evidence of a mitochondrial dysfunction, since all three biopsies examined showed COX-deficient fibers in excess of what would be expected for age. Electron microscopy showed mitochondrial accumulation without abnormal cristea or inclusions. The c.1616C > T variant in the AIRE gene was responsible for 100% of APECED cases in the French-Canadian population of Saguenay-Lac-Saint-Jean in Quebec, Canada.
CONCLUSIONS: We report the first series of French-Canadian cases affected with APECED. The Saguenay-Lac-Saint-Jean region was uncovered as a new founder population for this condition. Muscle biopsy findings expanded the range of previously described APECED-related myopathology. Long term follow-up of our genetically homogeneous French-Canadian cases may help determine if the c.1616C > T variant increases the risk of muscle involvement. A neonatal screening program is under consideration to prevent undesired life-threatening endocrine manifestations.
© 2021. Crown.

Entities:  

Keywords:  APECED; Founder population; French-Canadian; Saguenay-Lac-Saint-Jean

Mesh:

Year:  2021        PMID: 34846681     DOI: 10.1007/s12020-021-02826-7

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  31 in total

1.  The syndrome of familial juvenile hypoadrenocorticism, hypoparathyroidism and superficial moniliasis.

Authors:  V M ESSELBORN; B H LANDING; J WHITAKER; R R WILLIAMS
Journal:  J Clin Endocrinol Metab       Date:  1956-10       Impact factor: 5.958

2.  Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in the Irish population.

Authors:  Maria Dominguez; Ellen Crushell; Tanja Ilmarinen; Eleanor McGovern; Sinead Collins; Ben Chang; Padraig Fleming; Alan D Irvine; Donal Brosnahan; Ismo Ulmanen; Nuala Murphy; Colm Costigan
Journal:  J Pediatr Endocrinol Metab       Date:  2006-11       Impact factor: 1.634

3.  Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.

Authors:  Elise M N Ferre; Stacey R Rose; Sergio D Rosenzweig; Peter D Burbelo; Kimberly R Romito; Julie E Niemela; Lindsey B Rosen; Timothy J Break; Wenjuan Gu; Sally Hunsberger; Sarah K Browne; Amy P Hsu; Shakuntala Rampertaap; Muthulekha Swamydas; Amanda L Collar; Heidi H Kong; Chyi-Chia Richard Lee; David Chascsa; Thomas Simcox; Angela Pham; Anamaria Bondici; Mukil Natarajan; Joseph Monsale; David E Kleiner; Martha Quezado; Ilias Alevizos; Niki M Moutsopoulos; Lynne Yockey; Cathleen Frein; Ariane Soldatos; Katherine R Calvo; Jennifer Adjemian; Morgan N Similuk; David M Lang; Kelly D Stone; Gulbu Uzel; Jeffrey B Kopp; Rachel J Bishop; Steven M Holland; Kenneth N Olivier; Thomas A Fleisher; Theo Heller; Karen K Winer; Michail S Lionakis
Journal:  JCI Insight       Date:  2016-08-18

4.  Autoimmune polyendocrine syndrome type 1: an extensive longitudinal study in Sardinian patients.

Authors:  Antonella Meloni; Nick Willcox; Anthony Meager; Michela Atzeni; Anette S B Wolff; Eystein S Husebye; Maria Furcas; Maria Cristina Rosatelli; Antonio Cao; Mauro Congia
Journal:  J Clin Endocrinol Metab       Date:  2012-02-16       Impact factor: 5.958

5.  Autoimmune regulator-1 messenger ribonucleic acid analysis in a novel intronic mutation and two additional novel AIRE gene mutations in a cohort of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients.

Authors:  Katarina Trebusak Podkrajsek; Nina Bratanic; Ciril Krzisnik; Tadej Battelino
Journal:  J Clin Endocrinol Metab       Date:  2005-05-10       Impact factor: 5.958

6.  Severe autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy in an adolescent girl with a novel AIRE mutation: response to immunosuppressive therapy.

Authors:  L Ward; J Paquette; E Seidman; C Huot; F Alvarez; P Crock; E Delvin; O Kämpe; C Deal
Journal:  J Clin Endocrinol Metab       Date:  1999-03       Impact factor: 5.958

7.  Molecular background of polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome in a Polish population: novel AIRE mutations and an estimate of disease prevalence.

Authors:  B Stolarski; E Pronicka; L Korniszewski; A Pollak; G Kostrzewa; E Rowińska; P Włodarski; A Skórka; M Gremida; P Krajewski; R Ploski
Journal:  Clin Genet       Date:  2006-10       Impact factor: 4.438

8.  Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients.

Authors:  P Ahonen; S Myllärniemi; I Sipilä; J Perheentupa
Journal:  N Engl J Med       Date:  1990-06-28       Impact factor: 91.245

9.  Polyglandular autoimmune syndrome type I among Iranian Jews.

Authors:  J Zlotogora; M S Shapiro
Journal:  J Med Genet       Date:  1992-11       Impact factor: 6.318

10.  Myopathy in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.

Authors:  Mitsuru Watanabe; Hirofumi Ochi; Hajime Arahata; Tomohito Matsuo; Seiho Nagafuchi; Yasumasa Ohyagi; Jun-Ichi Kira
Journal:  Muscle Nerve       Date:  2012-06       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.